Progyny, Inc.(PGNY)Earnings, Financials & Key Ratios

PGNY•NASDAQ

$18.70

$1.53B mkt cap·28.8× P/E·Price updated May 6, 2026

SectorHealthcare IndustryHealthcare IT Sub-IndustryPayer and Benefits Administration

AboutProgyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Show more

Revenue$1.29B+10.4%
EBITDA$90M+27.7%
Net Income$59M+7.7%
EPS (Diluted)0.65+14.0%
Gross Margin23.63%+8.9%
EBITDA Margin7%+15.7%
Operating Margin6.62%+14.5%
Net Margin4.54%-2.5%
ROE12.48%+12.0%
ROIC18.1%+35.0%
Debt/Equity0.05+1.9%

Technical→

PGNY Key Insights

Progyny, Inc. (PGNY) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 30.2%
✓Share count reduced 6.3% through buybacks
✓Efficient asset utilization: 1.7x turnover

✗Weaknesses

✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

PGNY Price & Volume

Progyny, Inc. (PGNY) stock price & volume — 10-year historical chart

Loading chart...

PGNY Growth Metrics

Progyny, Inc. (PGNY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years30.17%

3 Years17.87%

TTM10.4%

Profit CAGR

10 Years-

5 Years4.72%

3 Years24.45%

TTM7.7%

EPS CAGR

10 Years-

5 Years6.7%

3 Years29.4%

TTM14.04%

Return on Capital

10 Years-0.14%

5 Years13.19%

3 Years14.61%

Last Year17.43%

PGNY Recent Earnings

Progyny, Inc. (PGNY) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 12/12 qtrs (100%)●Beat Revenue 8/12 qtrs (67%)

Q1 2026Latest

Feb 26, 2026

EPS

$0.15

Est $0.15

+2.0%

Revenue

$318M

Est $307M

+3.6%

Q4 2025

Nov 6, 2025

EPS

$0.45

Est $0.39

+15.4%

Revenue

$313M

Est $314M

-0.3%

Q3 2025

Aug 7, 2025

EPS

$0.48

Est $0.44

+9.1%

Revenue

$333M

Est $299M

+11.2%

Q2 2025

May 8, 2025

EPS

$0.48

Est $0.45

+6.7%

Revenue

$324M

Est $308M

+5.3%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 26, 2026	$0.15vs $0.15+2.0%	$318Mvs $307M+3.6%
Q4 2025	Nov 6, 2025	$0.45vs $0.39+15.4%	$313Mvs $314M-0.3%
Q3 2025	Aug 7, 2025	$0.48vs $0.44+9.1%	$333Mvs $299M+11.2%
Q2 2025	May 8, 2025	$0.48vs $0.45+6.7%	$324Mvs $308M+5.3%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
HIMSHims & Hers Health, Inc.Direct Competitor	6.94B	26.88	52.71	59%	5.47%	23.73%	2.07
LFSTLifeStance Health Group, Inc.Direct Competitor	2.85B	7.36	368	13.85%	0.68%	0.65%	0.13
GDRXGoodRx Holdings, Inc.Direct Competitor	880.73M	2.57	30.13	0.57%	3.74%	4.75%	0.10
CVSCVS Health CorporationProduct Competitor	111.32B	86.86	62.49	7.85%	0.72%	3.86%	1.24
CICigna CorporationProduct Competitor	74.35B	281.98	12.72	11.26%	2.26%	15.08%	0.75
UNHUnitedHealth Group IncorporatedProduct Competitor	333.37B	367.28	27.76	11.81%	2.68%	11.54%	0.77
ELVElevance Health Inc.Product Competitor	81.37B	374.71	14.92	12.62%	2.62%	11.92%	0.75
HUMHumana Inc.Product Competitor	29.57B	246.33	25.03	10.06%	0.82%	6.17%	0.73

Compare PGNY vs Peers

Progyny, Inc. (PGNY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HIMS

Most directly comparable listed peer for PGNY.

Scale Benchmark

vs UNH

Larger-name benchmark to compare PGNY against a more recognizable public peer.

Peer Set

Compare Top 5

vs HIMS, LFST, GDRX, CVS

PGNY Income Statement

Progyny, Inc. (PGNY) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	48.58M	105.4M	229.68M	344.86M	500.62M	786.91M	1.09B	1.17B	1.29B
Revenue Growth %	-	116.94%	117.92%	50.15%	45.17%	57.19%	38.34%	7.22%	10.4%
Cost of Goods Sold	41.18M	85.97M	184.18M	274.8M	388.49M	619.59M	849.8M	913.86M	984.18M
COGS % of Revenue	84.77%	81.56%	80.19%	79.68%	77.6%	78.74%	78.06%	78.29%	76.37%
Gross Profit	7.4M▲ 0%	19.43M▲ 162.6%	45.51M▲ 134.2%	70.06M▲ 54.0%	112.14M▲ 60.1%	167.32M▲ 49.2%	238.8M▲ 42.7%	253.36M▲ 6.1%	304.48M▲ 20.2%
Gross Margin %	15.23%	18.44%	19.81%	20.32%	22.4%	21.26%	21.94%	21.71%	23.63%
Gross Profit Growth %	-	162.62%	134.15%	53.96%	60.06%	49.22%	42.72%	6.1%	20.18%
Operating Expenses	18.41M	22.89M	35.83M	61.71M	79.8M	143.98M	176.62M	185.91M	219.21M
OpEx % of Revenue	37.88%	21.71%	15.6%	17.89%	15.94%	18.3%	16.22%	15.93%	17.01%
Selling, General & Admin	18.41M	22.89M	35.83M	61.71M	79.8M	143.98M	176.62M	185.91M	219.21M
SG&A % of Revenue	37.88%	21.71%	15.6%	17.89%	15.94%	18.3%	16.22%	15.93%	17.01%
Research & Development	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0
Operating Income	-11.01M▲ 0%	-3.45M▲ 68.6%	9.68M▲ 380.3%	8.35M▼ 13.7%	32.34M▲ 287.4%	23.34M▼ 27.8%	62.18M▲ 166.4%	67.45M▲ 8.5%	85.28M▲ 26.4%
Operating Margin %	-22.65%	-3.28%	4.21%	2.42%	6.46%	2.97%	5.71%	5.78%	6.62%
Operating Income Growth %	-	68.63%	380.33%	-13.73%	287.4%	-27.83%	166.42%	8.48%	26.42%
EBITDA	-9.45M	-1.57M	11.81M	10.25M	33.64M	24.94M	64.47M	70.63M	90.22M
EBITDA Margin %	-19.44%	-1.49%	5.14%	2.97%	6.72%	3.17%	5.92%	6.05%	7%
EBITDA Growth %	-	83.39%	852.71%	-13.18%	228.08%	-25.86%	158.46%	9.56%	27.74%
D&A (Non-Cash Add-back)	1.56M	1.88M	2.13M	1.91M	1.3M	1.6M	2.28M	3.17M	4.95M
EBIT	-11.01M	-3.45M	9.68M	8.35M	32.34M	23.34M	62.18M	67.45M	95.43M
Net Interest Income	-740K	-497K	-58K	121K	461K	814K	8.51M	15.75M	0
Interest Income	0	0	0	121K	461K	814K	8.51M	15.75M	0
Interest Expense	740K	497K	58K	0	0	0	0	0	0
Other Income/Expense	-1.45M	-3.44M	-18.23M	331K	95K	1.1M	8.51M	15.75M	10.15M
Pretax Income	-12.46M▲ 0%	-6.89M▲ 44.7%	-8.56M▼ 24.1%	8.68M▲ 201.4%	32.44M▲ 273.7%	24.44M▼ 24.6%	70.69M▲ 189.2%	83.2M▲ 17.7%	95.43M▲ 14.7%
Pretax Margin %	-25.64%	-6.54%	-3.73%	2.52%	6.48%	3.11%	6.49%	7.13%	7.41%
Income Tax	-3K	-1.78M	12K	-37.78M	-33.33M	-5.92M	8.65M	28.87M	36.91M
Effective Tax Rate %	0.02%	25.78%	-0.14%	-435.3%	-102.77%	-24.21%	12.24%	34.69%	38.68%
Net Income	-12.45M▲ 0%	661K▲ 105.3%	-8.57M▼ 1396.4%	46.46M▲ 642.2%	65.77M▲ 41.6%	30.36M▼ 53.8%	62.04M▲ 104.4%	54.34M▼ 12.4%	58.52M▲ 7.7%
Net Margin %	-25.63%	0.63%	-3.73%	13.47%	13.14%	3.86%	5.7%	4.66%	4.54%
Net Income Growth %	-	105.31%	-1396.37%	642.18%	41.56%	-53.84%	104.35%	-12.41%	7.7%
Net Income (Continuing)	-12.46M	-5.12M	-8.57M	46.46M	65.77M	30.36M	62.04M	54.34M	58.52M
Discontinued Operations	4K	5.78M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-2.19▲ 0%	0.01▲ 100.4%	-0.10▼ 1334.6%	0.47▲ 570.0%	0.66▲ 40.4%	0.30▼ 54.5%	0.62▲ 106.7%	0.57▼ 8.1%	0.65▲ 14.0%
EPS Growth %	-	100.37%	-	570%	40.43%	-54.55%	106.67%	-8.06%	14.04%
EPS (Basic)	-2.19	0.01	-0.10	0.54	0.74	0.33	0.65	0.59	0.68
Diluted Shares Outstanding	5.69M	81.56M	83.57M	99.06M	100.36M	99.96M	100.67M	95.45M	89.46M
Basic Shares Outstanding	5.69M	81.56M	83.57M	85.72M	89.11M	92.2M	95.02M	91.48M	85.23M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

PGNY Balance Sheet

Progyny, Inc. (PGNY) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	16.77M	24.54M	132.44M	190.22M	258.54M	433.86M	640.41M	472.72M	551.77M
Cash & Short-Term Investments	4.69M	127K	80.38M	109.3M	119.42M	189.3M	371.09M	227.95M	310.1M
Cash Only	4.69M	127K	80.38M	70.31M	91.41M	120.08M	97.3M	162.31M	112.24M
Short-Term Investments	0	0	0	38.99M	28M	69.22M	273.79M	65.64M	197.86M
Accounts Receivable	11.37M	23.32M	47.06M	75.66M	134.56M	240.07M	241.87M	235.32M	220.29M
Days Sales Outstanding	85.44	80.77	74.78	80.08	98.1	111.35	81.1	73.59	62.39
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	200K	0	0	0	4.49M	27.45M	9.44M	21.39M
Total Non-Current Assets	18.19M	16.79M	17.99M	63.7M	99.53M	109.13M	116.21M	134.38M	190.66M
Property, Plant & Equipment	597K	776K	3.08M	12.07M	12.83M	15.27M	27.82M	29.63M	54.92M
Fixed Asset Turnover	81.38x	135.82x	74.50x	28.58x	39.01x	51.52x	39.13x	39.39x	23.47x
Goodwill	11.88M	11.88M	11.88M	11.88M	11.88M	11.88M	11.88M	15.53M	19.98M
Intangible Assets	5.34M	3.86M	2.38M	1.21M	599K	99K	0	1.3M	6.22M
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	372K	272K	652K	573K	2.94M	3.99M	3.4M	2.98M	16.54M
Total Assets	34.96M▲ 0%	41.32M▲ 18.2%	150.43M▲ 264.0%	253.93M▲ 68.8%	358.06M▲ 41.0%	542.99M▲ 51.6%	756.62M▲ 39.3%	607.1M▼ 19.8%	742.43M▲ 22.3%
Asset Turnover	1.39x	2.55x	1.53x	1.36x	1.40x	1.45x	1.44x	1.92x	1.74x
Asset Growth %	-	18.2%	264.04%	68.8%	41.01%	51.64%	39.34%	-19.76%	22.29%
Total Current Liabilities	17.77M	30.2M	36.16M	77.79M	98.82M	159.54M	185.95M	168.63M	202.39M
Accounts Payable	5.13M	15.58M	19.39M	43.51M	61.4M	109.29M	125.43M	95.1M	124.07M
Days Payables Outstanding	45.47	66.14	38.42	57.8	57.69	64.38	53.87	37.98	46.01
Short-Term Debt	3.56M	253K	0	0	0	0	0	0	0
Deferred Revenue (Current)	7.13M	9.39M	0	0	0	0	0	0	0
Other Current Liabilities	6.73M	11.64M	13M	7.69M	12.26M	8.88M	13.05M	19.87M	78.32M
Current Ratio	0.94x	0.81x	3.66x	2.45x	2.62x	2.72x	3.44x	2.80x	2.73x
Quick Ratio	0.94x	0.81x	3.66x	2.45x	2.62x	2.72x	3.44x	2.80x	2.73x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities	6.5M	106.24M	0	9.19M	7.42M	6.48M	17.24M	16.41M	24M
Long-Term Debt	1.63M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	8.32M	7.42M	6.48M	17.24M	16.41M	24M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	4.87M	0	0	876K	0	0	0	0	0
Total Liabilities	24.27M	30.2M	36.16M	86.98M	106.24M	166.02M	203.19M	185.04M	226.39M
Total Debt	5.19M	253K	0	9.55M	8.65M	7.71M	19.39M	19.27M	24M
Net Debt	497K	126K	-80.38M	-60.76M	-82.76M	-112.36M	-77.91M	-143.04M	-88.24M
Debt / Equity	0.49x	0.02x	-	0.06x	0.03x	0.02x	0.04x	0.05x	0.05x
Debt / EBITDA	-	-	-	0.93x	0.26x	0.31x	0.30x	0.27x	0.27x
Net Debt / EBITDA	-	-	-6.81x	-5.93x	-2.46x	-4.51x	-1.21x	-2.03x	-0.98x
Interest Coverage	-14.87x	-6.95x	166.84x	-	-	-	-	-	-
Total Equity	10.69M▲ 0%	11.12M▲ 4.0%	114.27M▲ 927.4%	166.95M▲ 46.1%	251.82M▲ 50.8%	376.97M▲ 49.7%	553.43M▲ 46.8%	422.06M▼ 23.7%	516.04M▲ 22.3%
Equity Growth %	-	4.04%	927.43%	46.1%	50.84%	49.7%	46.81%	-23.74%	22.27%
Book Value per Share	1.88	0.14	1.37	1.69	2.51	3.77	5.50	4.42	5.77
Total Shareholders' Equity	10.69M	11.12M	114.27M	166.95M	251.82M	376.97M	553.43M	422.06M	516.04M
Common Stock	1K	1K	8K	9K	9K	9K	9K	9K	9K
Retained Earnings	-104.56M	-104.85M	-113.48M	-68.19M	-2.42M	27.93M	89.97M	144.31M	202.83M
Treasury Stock	0	-884K	-1.01M	-1.01M	-1.01M	-1.01M	-1.01M	-303.89M	-388.07M
Accumulated OCI	-83K	-483K	-150.43M	1K	-93K	501K	2.82M	39K	498K
Minority Interest	0	0	0	0	0	0	0	0	0

PGNY Cash Flow Statement

Progyny, Inc. (PGNY) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	-9.47M	2.27M	-1.53M	36.2M	26.04M	80.39M	188.81M	179.1M	210.19M
Operating CF Margin %	-19.5%	2.16%	-0.67%	10.5%	5.2%	10.22%	17.34%	15.34%	16.31%
Operating CF Growth %	-	123.98%	-167.52%	2460.04%	-28.08%	208.77%	134.86%	-5.14%	17.36%
Net Income	-12.45M	661K	-8.57M	46.46M	65.77M	30.36M	62.04M	54.34M	58.52M
Depreciation & Amortization	1.56M	1.88M	2.13M	1.91M	1.3M	1.6M	2.28M	3.17M	4.95M
Stock-Based Compensation	1.56M	3M	5.06M	12.82M	0	100.75M	122.61M	128.13M	131.87M
Deferred Taxes	-3K	-1.78M	12K	-37.97M	-33.3M	-6.62M	3.75M	-10.46M	-8.12M
Other Non-Cash Items	1.29M	-1.85M	19.78M	5.64M	43.53M	13.79M	15.56M	15.7M	20.17M
Working Capital Changes	-1.43M	354K	-19.95M	7.35M	-51.26M	-59.49M	-17.42M	-11.78M	2.8M
Change in Receivables	-2.04M	-12.78M	-25.34M	-35.34M	-68.68M	-119.3M	-21.74M	-9.87M	-5.12M
Change in Inventory	1.81M	2.58M	0	0	0	0	0	0	0
Change in Payables	-909K	10.45M	3.5M	25.01M	17.84M	47.69M	16.23M	-30.27M	28.75M
Cash from Investing	-612K	1.9M	-2.76M	-40.03M	8.77M	-43.87M	-200.53M	195.79M	-159.01M
Capital Expenditures	-612K	-579K	-2.96M	-1.04M	-2.13M	-3.24M	-3.64M	-5.41M	-18.41M
CapEx % of Revenue	1.26%	0.55%	1.29%	0.3%	0.43%	0.41%	0.33%	0.46%	1.43%
Acquisitions	0	0	0	0	0	0	0	-5.3M	-9.34M
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	2.48M	200K	0	0	0	0	0	0
Cash from Financing	11.77M	-8.74M	84.55M	-6.25M	-13.7M	-7.86M	-11.07M	-309.88M	-99.36M
Debt Issued (Net)	-3.26M	-5.1M	-253K	0	0	0	0	0	0
Equity Issued (Net)	15M	-3.71M	81.03M	2.68M	4.27M	4.22M	6.13M	-300.28M	-80.43M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-3.71M	-185K	0	0	0	0	-300.28M	-81.66M
Other Financing	25K	65K	3.76M	-8.93M	-17.97M	-12.09M	-17.2M	-9.6M	-18.93M
Net Change in Cash	1.68M▲ 0%	-4.56M▼ 371.7%	80.25M▲ 1858.4%	-10.08M▼ 112.6%	21.11M▲ 309.5%	28.66M▲ 35.8%	-22.78M▼ 179.5%	65.02M▲ 385.4%	-48.12M▼ 174.0%
Free Cash Flow	-10.09M▲ 0%	1.69M▲ 116.8%	-4.49M▼ 365.2%	35.17M▲ 883.2%	23.91M▼ 32.0%	77.15M▲ 222.7%	185.17M▲ 140.0%	173.7M▼ 6.2%	191.78M▲ 10.4%
FCF Margin %	-20.76%	1.61%	-1.95%	10.2%	4.78%	9.8%	17.01%	14.88%	14.88%
FCF Growth %	-	116.79%	-365.21%	883.21%	-32.01%	222.71%	140%	-6.19%	10.41%
FCF per Share	-1.77	0.02	-0.05	0.36	0.24	0.77	1.84	1.82	2.14
FCF Conversion (FCF/Net Income)	0.76x	3.44x	0.18x	0.78x	0.40x	2.65x	3.04x	3.30x	3.59x
Interest Paid	0	0	176K	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	40.45M	0

PGNY Key Ratios

Progyny, Inc. (PGNY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-116.48%	6.06%	-13.67%	33.04%	31.41%	9.66%	13.34%	11.14%	12.48%
Return on Invested Capital (ROIC)	-73.78%	-23.08%	32.16%	8.94%	17.62%	8.07%	12.6%	13.41%	18.1%
Gross Margin	15.23%	18.44%	19.81%	20.32%	22.4%	21.26%	21.94%	21.71%	23.63%
Net Margin	-25.63%	0.63%	-3.73%	13.47%	13.14%	3.86%	5.7%	4.66%	4.54%
Debt / Equity	0.49x	0.02x	-	0.06x	0.03x	0.02x	0.04x	0.05x	0.05x
Interest Coverage	-14.87x	-6.95x	166.84x	-	-	-	-	-	-
FCF Conversion	0.76x	3.44x	0.18x	0.78x	0.40x	2.65x	3.04x	3.30x	3.59x
Revenue Growth	-	116.94%	117.92%	50.15%	45.17%	57.19%	38.34%	7.22%	10.4%

PGNY SEC Filings & Documents

Progyny, Inc. (PGNY) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Mar 13, 2026·SEC

Material company update

Feb 26, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 27, 2026·SEC

FY 2025

Mar 3, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 7, 2025·SEC

FY 2025

Aug 8, 2025·SEC

FY 2025

May 9, 2025·SEC

PGNY Frequently Asked Questions

Progyny, Inc. (PGNY) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Progyny, Inc. (PGNY) reported $1.29B in revenue for fiscal year 2025. This represents a 2552% increase from $48.6M in 2017.

Progyny, Inc. (PGNY) grew revenue by 10.4% over the past year. This is steady growth.

Yes, Progyny, Inc. (PGNY) is profitable, generating $58.5M in net income for fiscal year 2025 (4.5% net margin).

Dividend & Returns

Progyny, Inc. (PGNY) has a return on equity (ROE) of 12.5%. This is reasonable for most industries.

Progyny, Inc. (PGNY) generated $188.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More PGNY

Progyny, Inc. (PGNY) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Progyny, Inc.(PGNY)Earnings, Financials & Key Ratios

PGNY Key Insights

✓Strengths

✗Weaknesses

PGNY Price & Volume

PGNY Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

PGNY Recent Earnings

PGNY Peer Comparison

Compare PGNY vs Peers

vs HIMS

vs UNH

Compare Top 5

PGNY Income Statement

PGNY Balance Sheet

PGNY Cash Flow Statement

PGNY Key Ratios

PGNY SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

PGNY Frequently Asked Questions

Explore More PGNY

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation